PureTech

#Celea Therapeutics #Idiopathic pulmonary fibrosis #Lung disease #PureTech #Respiratory

Celea Therapeutics launches into respiratory disease space

PureTech Health has announced the launch of a new founded entity Celea Therapeutics to deliver therapies for serious respiratory diseases.   Its lead programme, deupirfenidone (LYT-100), is a Phase III-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for… Read More

#Business & Investment #News

Brain inflammation
#Bristol Myers Squibb #FDA #Neuroscience #PureTech #Schizophrenia

New approach to schizophrenia treatment secures US approval

The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the… Read More

#News #Regulatory #Trending News